Zevra Therapeutics Inc Expected EPS of $1.50 for Q2 2025

Summary

Zevra Therapeutics Inc. is anticipated to report earnings of $1.50 per share and a significant revenue increase of 406.5% to $22.535 million for the quarter ending June 30, 2025. The average analyst rating is ‘buy,’ with a median 12-month price target of $25.00, reflecting a potential 51.5% rise from the last closing price of $12.13. The earnings estimates have remained unchanged over the past three months, with no recent holds or sells among analysts. Reuters

Impact Analysis

1. Business Overview Analysis

• Business Model: Zevra Therapeutics Inc. operates as a commercial-stage company focused on providing therapies for people living with rare diseases. The core revenue streams likely come from drug sales and reimbursements for treatments, such as Miplyffa and Arimoclomol. Benzinga+ 2
• Market Position: The company has a strong position in the niche market of rare diseases, which often allows for higher pricing power and less competition compared to broader pharmaceutical markets. Recent financial performance suggests positive market reception and growing demand. Reuters+ 2
• Recent Events Impact: Zevra’s revenue growth has been significantly impacted by the successful sales of Miplyffa and reimbursements for Arimoclomol. Positive earnings reports and analyst ratings sustain investor confidence and reflect strong business performance. Benzinga+ 2

2. Financial Statement Analysis

• Income Statement: Zevra’s revenue for the quarter ending June 30, 2025, is expected to rise dramatically by 406.5% to $22.535 million. In the previous quarter, revenue soared to $20.40 million, supported by product sales and reimbursements. Profit metrics indicate improved financial health with earnings per share estimated at $1.50. Benzinga+ 2
• Balance Sheet: Detailed balance sheet data is not provided, but assessing from revenue growth, the company’s asset quality appears to be strong. Liabilities and working capital structure likely reflect good management, given the significant revenue increase and improved earnings. Reuters+ 2
• Cash Flow: Operational cash generation is likely robust given the impressive revenue figures. Investment needs likely focus on R&D and expanding market reach. Financing activities could be geared towards further development and scaling operations. Reuters
• Financial Ratios:
• Profitability: ROE and ROA should be strong given the earnings growth. Operating Margins are likely improving given the successful sales and reimbursement strategies.
• Liquidity: Current and Quick Ratios would ideally be healthy, reflecting good cash flow management.
• Solvency: Debt/Equity ratio and Interest Coverage should remain favorable, indicating manageable debt levels.
• Efficiency: Asset Turnover and Inventory Turnover likely show improvement given the rapid revenue growth. Reuters+ 2

3. Valuation Assessment

• The median 12-month price target of $25.00 suggests a significant upside potential of 51.5% from the last closing price of $12.13. Current valuation metrics should be compared against historical averages and industry peers to assess relative market positioning. Reuters

4. Opportunity Analysis

• Market expansion opportunities in rare disease treatments could further increase revenue streams.
• Continuous development of new therapies and drug approvals may strengthen market position.
• Strategic opportunities such as partnerships, acquisitions, or further investment in R&D could drive growth.
• Operational and financial improvements supported by consistent revenue growth and favorable analyst ratings. Reuters